COVID-19 patent fights continue as Arbutus, Genevant come after Pfizer and BioNTech in new lawsuit Back in 2022 ... Moderna has also been sued by CureVac and Alnylam, along with COVID vaccine ...
A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged ...
The ruling represents the first decision on validity in ongoing patent litigation between CureVac and BioNTech in Germany, involving eight CureVac intellectual property rights. Price Action ...
Moderna's patent lawsuit claiming Pfizer and BioNTech copied its COVID-19 vaccine technology will be put on hold while the ...
CureVac (NASDAQ:CVAC) and the University of Texas MD Anderson Cancer Center announced a co-development and licensing pact to develop novel, off-the-shelf, mRNA-based cancer vaccines for selected ...
CureVac and GSK have been racing behind Moderna to try to get the first mRNA flu vaccine to market. But, now, the European partners have come up against the exact same problem as their U.S ...
Leerink Partners analyst Mani Foroohar maintained a Buy rating on CureVac (CVAC – Research Report) on April 16. The company’s shares closed yesterday at $2.57. According to TipRanks ...
CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland, and the U.S. Further information can ...
Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertise Collaboration aims to develop novel ...
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its ...
CureVac (NASDAQ:CVAC) said on Thursday that its seasonal influenza vaccine candidate developed with GSK (NYSE:GSK) outperformed licensed products against influenza A strains in terms of antibody ...